Posted by Michael Wonder on 20 Oct 2016
Mylan’s settlement with DOJ not tough enough, Senator says
20 October 2016 - Connecticut’s Blumenthal calling for criminal inquiry.
Mylan NV’s $465 million settlement with the U.S. Department of Justice over Medicaid rebates for its EpiPen allergy shot is a “sweetheart deal,” and the company should face a criminal investigation, Senator Richard Blumenthal said Wednesday.
Medicaid, which provides health insurance to the poor in the U.S., gets a 23 percent discount on brand-name drugs and a 13 percent discount on generic drugs. EpiPen had been classified incorrectly as a generic since at least 1997, both by Mylan and previous makers of the life-saving medicine, according to the Centers for Medicare and Medicaid Service.
